846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function

MLA

Philip Home, et al. “846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function.” Diabetes, vol. 71, June 2022. EBSCOhost, https://doi.org/10.2337/db22-846-p.

APA

Philip Home, Julio Rosenstock, Francesco Giorgino, Matthias Blüher, Khier Djaballah, Katrin Pegelow, Lydie Melas-Melt, & Rory J. Mccrimmon. (2022). 846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function. Diabetes, 71. https://doi.org/10.2337/db22-846-p

Chicago

Philip Home, Julio Rosenstock, Francesco Giorgino, Matthias Blüher, Khier Djaballah, Katrin Pegelow, Lydie Melas-Melt, and Rory J. Mccrimmon. 2022. “846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function.” Diabetes 71 (June). doi:10.2337/db22-846-p.